Lilly Bamlanivimab Antibody Playbook
This antibody playbook provides information for state, territorial and local public health programs to plan and operationalize a bamlanivimab antibody response to COVID-19. The sections of this document cover specific areas of COVID-19 antibody program planning and implementation, as well as links to resources to assist with those efforts.
Related Content
A New Approach to Mitigate Drug Shortages
Novel Low-Dose Syringe: Enhancing Pediatric Medication Safety
The Facts About COVID-19 and Children
A New Approach to Mitigate Drug Shortages
A 90-day pilot program provides pediatric hospitals with over 140,000 essential medicine treatments.
Novel Low-Dose Syringe: Enhancing Pediatric Medication Safety
Children's hospitals identified a need for low-dose syringes and their collaboration led to the development of a safer option for medication administration in pediatric health care.
The Facts About COVID-19 and Children
Read the latest data on kids' COVID-19 cases, hospitalizations and vaccination numbers.
